Pharmacogenomic assessment of Mexican and Peruvian populations

Pharmacogenomics

Volumn 16, Issue 5, 2015, Pages 441-448

  Marsh, Sharon ^a,b   King, Cristi R ^c   Van Booven, Derek J ^b,d   Revollo, Jane Y ^e   Gilman, Robert H ^f   McLeod, Howard L ^b,g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Pharmacogenetics for Every Nation Initiative   (United States)

^c WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e JACKSON MEMORIAL HOSPITAL   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Genotype; Hispanic; Mexico; Peru; Pharmacogenomics; Polymorphism; Population

Indexed keywords

ADENINE; AZATHIOPRINE; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 1B1; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOSINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE P1; GUANINE; MULTIDRUG RESISTANCE PROTEIN 1; THYMINE; WARFARIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ARTICLE; CENTRAL AMERICA; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MALE; MEXICAN; NUCLEIC ACID BASE SUBSTITUTION; PERUVIAN; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AMERICA; ADULT; ALLELE; EPIDEMIOLOGY; MEXICO; PERU; PHARMACOGENETICS; PILOT STUDY;

ADULT; ALLELES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MEXICO; PERU; PHARMACOGENETICS; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84929086164     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.10     Document Type: Article

References (67)

1. Kidd KK, Pakstis AJ, Yun L. An historical perspective on the world-wide distribution of allele frequencies at the human dopamine D4 receptor locus. Hum. Genet. 133(4), 431-433 (2014)
2. Stathias V, Sotiris GR, Karagiannidis I et al. Exploring genomic structure differences and similarities between the Greek and European HapMap populations: implications for association studies. Ann. Hum. Genet. 76(6), 472-483 (2012)
3. Engen RM, Marsh S, Van Booven DJ, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. Curr. Drug Targets 7(12), 1641-1648 (2006)
4. Cavaco I, Piedade R, Gil JP, Ribeiro V. CYP2C8 polymorphism among the Portuguese. Clin. Chem. Lab. Med. 44(2), 168-170 (2006)
5. King CR, Yu J, Freimuth RR, McLeod HL, Marsh S. Interethnic variability of ERCC2 polymorphisms. Pharmacogenomics J. 5(1), 54-59 (2005)
6. Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS. Population variation in VKORC1 haplotype structure. J. Thromb. Haemost. 4(2), 473-474 (2006)
7. Lee MY, Mukherjee N, Pakstis AJ et al. Global patterns of variation in allele and haplotype frequencies and linkage disequilibrium across the CYP2E1 gene. Pharmacogenomics J. 8(5), 349-356 (2008)
8. Marsh S, Van Booven DJ, McLeod HL. Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics 7(4), 625-631 (2006)
9. Marsh S. Pharmacogenetics: global clinical markers. Pharmacogenomics 9(4), 371-373 (2008)
10. Mitropoulos K, Innocenti F, Van Schaik RH et al. Institutional Profile: Golden Helix Institute of Biomedical Research: interdisciplinary research and educational activities in pharmacogenomics and personalized medicine. Pharmacogenomics 13(4), 387-392 (2012)
11. Roederer MW, Sanchez-Giron F, Kalideen K et al. Pharmacogenetics and rational drug use around the world. Pharmacogenomics 12(6), 897-905 (2011)
12. Roederer MW, McLeod HL. Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics 11(5), 633-636 (2010)
13. Mitropoulos K, Johnson L, Vozikis A, Patrinos GP. Relevance of pharmacogenomics for developing countries in Europe. Drug Metabol. Drug Interact. 26(4), 143-146 (2011)
14. US Census Website. www.census.gov
15. CIA World Factbook: Mexico www.cia.gov
16. Bertoni B, Budowle B, Sans M, Barton SA, Chakraborty R. Admixture in Hispanics: distribution of ancestral population contributions in the Continental United States. Hum. Biol. 75(1), 1-11 (2003)
17. Moreno-Estrada A, Gignoux CR, Fernandez-Lopez JC et al. Human genetics. The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. Science 344(6189), 1280-1285 (2014)
18. CIA World Factbook: Peru. www.cia.gov
19. Sandoval JR, Salazar-Granara A, Acosta O et al. Tracing the genomic ancestry of Peruvians reveals a major legacy of pre-Columbian ancestors. J. Hum. Genet. 58(9), 627-634 (2013)
20. Callegari-Jacques SM, Tarazona-Santos EM, Gilman RH et al. Autosome STRs in native South America-Testing models of association with geography and language. Am. J. Phys. Anthropol. 145(3), 371-381 (2011)
21. Pereira L, Zamudio R, Soares-Souza G et al. Socioeconomic and nutritional factors account for the association of gastric cancer with Amerindian ancestry in a Latin American admixed population. PLoS ONE 7(8), e41200 (2012)
22. Scliar MO, Gouveia MH, Benazzo A et al. Bayesian inferences suggest that Amazon Yunga Natives diverged from Andeans less than 5000 ybp: implications for South American prehistory. BMC Evol. Biol. 14(1), 174 (2014)
23. Pino-Yanes M, Thakur N, Gignoux CR et al. Genetic ancestry influences asthma susceptibility and lung function among Latinos. J. Allergy Clin. Immunol. 135(1), 228-235 (2014)
24. Cuautle-Rodriguez P, Llerena A, Molina-Guarneros J. Present status and perspective of pharmacogenetics in Mexico. Drug Metabol. Drug Interact. 29(1), 37-45 (2014)
25. Poland RA, Lin KM, Nuccio C, Wilkinson GR. Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans. Clin. Pharmacol. Ther. 72(3), 288-293 (2002)
26. Mendoza R, Wan YJ, Poland RE et al. CYP2D6 polymorphism in a Mexican American population. Clin. Pharmacol. Ther. 70(6), 552-560 (2001)
27. Dorado P, Sosa-Macias MG, Penas-Lledo EM et al. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics J. 11(2), 108-112 (2011)
28. Williams MA, Sanchez SE, Zhang C, Bazul V. Methylenetetrahydrofolate reductase 677 C >T polymorphism and plasma folate in relation to pre-eclampsia risk among Peruvian women. J. Matern. Fetal. Neonatal. Med. 15(5), 337-344 (2004)
29. Gueant-Rodriguez RM, Gueant JL, Debard R et al. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations. Am. J. Clin. Nutr. 83(3), 701-707 (2006)
30. Monsalve MV, Salzano FM, Rupert JL et al. Methylenetetrahydrofolate reductase (MTHFR) allele frequencies in Amerindians. Ann. Hum. Genet. 67(Pt 4), 367-371 (2003)
31. Marinaki AM, Ansari A, Duley JA et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14, 181-187 (2004)
32. Marsh S, King CR, Ahluwalia R, McLeod HL. Distribution of ITPA P32T alleles in multiple world populations. J. Hum. Genet. 49(10), 579-581 (2004)
33. Shahin MH, Cavallari LH, Perera MA et al. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thromb. Haemost. 109(6), 1045-1050 (2013)
34. WHO Essential Medicines List. www.who.int/selection-medicines/list/en/
35. Roth DE, Soto G, Arenas F et al. Association between vitamin D receptor gene polymorphisms and response to treatment of pulmonary tuberculosis. J. Infect. Dis. 190(5), 920-927 (2004)
36. Coriell Institute. https://catalog.coriell.org/1/NIGMS
37. Llerena A, Dorado P, O'Kirwan F, Jepson R, Licinio J, Wong ML. Lower frequency of CYP2C9 2 in Mexican-Americans compared with Spaniards. Pharmacogenomics J. 4(6), 403-406 (2004)
38. Marsh S, King CR, Garsa AA, McLeod HL. Pyrosequencing of clinically relevant polymorphisms. Methods Mol. Biol. 311, 97-114 (2005)
39. Saeki M, Saito Y, Jinno H et al. Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing. Clin. Chem. 49(7), 1182-1185 (2003)
40. Oliveira E, Marsh S, Van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics 8(7), 703-712 (2007)
41. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med. Genet. 6(1), 19 (2005)
42. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20(3), 191-197 (1995)
43. Hardy-Weinberg software. http://krunch.med.yale.edu/hwsim
44. Schaid DJ, Mcdonnell SK, Wang L, Cunningham JM, Thibodeau SN. Caution on pedigree haplotype inference with software that assumes linkage equilibrium. Am J. Hum. Genet. 71(4), 992-995 (2002)
45. 100 Genomes Project: Peru. https://catalog.coriell.org
46. 1000 Genomes Project: Mexico. https://catalog.coriell.org
47. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306(24), 2704-2714 (2011)
48. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum. Mol. Genet. 8(2), 367-370 (1999)
49. Indjova D, Atanasova S, Shipkova M, Armstrong VW, Oellerich M, Svinarov D. Phenotypic and genotypic analysis of thiopurine s-methyltransferase polymorphism in the bulgarian population. Ther. Drug Monit. 25(5), 631-636 (2003)
50. Kumagai K, Hiyama K, Ishioka S et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 11(3), 275-278 (2001)
51. Chang JG, Lee LS, Chen CM et al. Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics 12(3), 191-195 (2002)
52. Lu HF, Shih MC, Hsueh SC, Chen CM, Chang JY, Chang JG. Molecular analysis of the thiopurine S-methyltransferase alleles in Bolivians and Tibetans. J. Clin. Pharm. Ther. 30(5), 491-496 (2005)
53. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118(4), 705-713 (2000)
54. Larovere LE, De Kremer RD, Lambooy LH, De Abreu RA. Genetic polymorphism of thiopurine S-methyltransferase in Argentina. Ann. Clin. Biochem. 40(Pt 4), 388-393 (2003)
55. Isaza C, Henao J, Lopez AM, Cacabelos R. Allelic variants of the thiopurine methyltransferase (TPMT) gene in the Colombian population. Methods Find. Exp. Clin. Pharmacol. 25(6), 423-429 (2003)
56. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum. Mol. Genet. 8(2), 371-376 (1999)
57. Boson WL, Romano-Silva MA, Correa H, Falcao RP, Teixeira-Vidigal PV, De Marco L. Thiopurine methyltransferase polymorphisms in a Brazilian population. Pharmacogenomics J. 3(3), 178-182 (2003)
58. Farfan MJ, Salas C, Canales C et al. Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia. BMC Cancer 14, 299 (2014)
59. Garrido C, Santizo VG, Mullers P et al. Frequency of thiopurine S-methyltransferase mutant alleles in indigenous and admixed Guatemalan patients with acute lymphoblastic leukemia. Med. Oncol. 30(1), 474 (2013)
60. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1 28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007)
61. Sai K, Saeki M, Saito Y et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75(6), 501-515 (2004)
62. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004)
63. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. A haplotype map of the human genome. Nature 437(7063), 1299-1320 (2005)
64. Mendoza-Reinoso V, Patil TS, Guevara-Fujita ML et al. Novel and known MYOC exon 3 mutations in an admixed Peruvian primary open-angle glaucoma population. Mol. Vision 18, 2067-2075 (2012)
65. Estrela RC, Ribeiro FS, Carvalho RS et al. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics 9(3), 267-276 (2008)
66. Sosa-Macias M, Dorado P, Alanis-Banuelos RE, Llerena A, Lares-Asseff I. Influence of CYP2D6 deletion, multiplication,-1584C >G, 31G >A and 2988G >a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos. Pharmacology 86(1), 30-36 (2010)
67. Sosa-Macias M, Llerena A. Cytochrome P450 genetic polymorphisms of Mexican indigenous populations. Drug Metabol. Drug Interact. 28(4), 193-208 (2013).